The Real-World Provider

Peptides in the Clinic: What Providers Need to Know Before Offering Peptide Therapy: Episode 14

15 min · 12 de abr de 2026
Portada del episodio Peptides in the Clinic: What Providers Need to Know Before Offering Peptide Therapy: Episode 14

Descripción

Peptide therapy is one of the fastest-growing areas in clinical practice — and one of the most confusing when it comes to what's legal, what's evidence-based, and what actually belongs in your clinic. In this episode of The Real World Provider, Danni Owens, FNP-BC, breaks down the peptides every healthcare provider should know about in 2026: from healing peptides like BPC-157 and TB-500, to growth hormone secretagogues like ipamorelin and CJC-1295, to immune modulators, cognitive enhancers, longevity peptides, and more. This episode covers the 2026 FDA reclassification announcement, the difference between Category 1 and Category 2 peptides, what RFK Jr.'s announcement actually means for your practice, and the five things every provider needs to do before prescribing peptide therapy. If you're an NP, PA, or physician offering — or considering — peptide therapy in your clinic, this is your real-world guide. Peptides covered: BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295, Sermorelin, Thymosin Alpha-1, AOD-9604, Selank, Semax, KPV, MOTS-c, Epitalon, DSIP, and Kisspeptin-10.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de The Real-World Provider!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

14 episodios

episode Peptides in the Clinic: What Providers Need to Know Before Offering Peptide Therapy: Episode 14 artwork

Peptides in the Clinic: What Providers Need to Know Before Offering Peptide Therapy: Episode 14

Peptide therapy is one of the fastest-growing areas in clinical practice — and one of the most confusing when it comes to what's legal, what's evidence-based, and what actually belongs in your clinic. In this episode of The Real World Provider, Danni Owens, FNP-BC, breaks down the peptides every healthcare provider should know about in 2026: from healing peptides like BPC-157 and TB-500, to growth hormone secretagogues like ipamorelin and CJC-1295, to immune modulators, cognitive enhancers, longevity peptides, and more. This episode covers the 2026 FDA reclassification announcement, the difference between Category 1 and Category 2 peptides, what RFK Jr.'s announcement actually means for your practice, and the five things every provider needs to do before prescribing peptide therapy. If you're an NP, PA, or physician offering — or considering — peptide therapy in your clinic, this is your real-world guide. Peptides covered: BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295, Sermorelin, Thymosin Alpha-1, AOD-9604, Selank, Semax, KPV, MOTS-c, Epitalon, DSIP, and Kisspeptin-10.

12 de abr de 202615 min
episode Running a Weight Loss Clinic on GLP-1s: What Every Provider Needs to Know Right Now: Episode 13 artwork

Running a Weight Loss Clinic on GLP-1s: What Every Provider Needs to Know Right Now: Episode 13

Are you a provider running — or thinking about starting — a weight loss clinic using GLP-1 medications? In this episode of The Real World Provider, Danni Owens, FNP-BC, breaks down everything healthcare providers need to know about semaglutide and tirzepatide in 2026. From the FDA's oral Wegovy approval to the compounding pharmacy legal battles, prescribing authority by state, clinical protocols, cash-pay pricing models, and where the GLP-1 market is heading — this is the real-world guide to building a sustainable weight loss practice with GLP-1 receptor agonists. Whether you're an NP, PA, or MD looking to add GLP-1 prescribing to your clinic, or you're already offering weight management services and want to stay ahead of the regulatory changes, this episode covers it all. Topics include: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), 503A vs. 503B compounding pharmacies, FDA shortage list updates, patient selection criteria, titration protocols, side effect management, cash-pay clinic models, oral GLP-1 medications, insurance coverage trends, and how to compete with telehealth and retail clinics.

12 de abr de 202611 min